SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Venus Concept, Inc. is a global medical technology company, which engages in the business of developing, commercializing, and selling minimally invasive and non-invasive medical aesthetic and hair restoration technologies. It operates under the United States and International geographical segments. The company was founded on November 22, 2002 and is headquartered in Toronto, Canada.

Venus Concept Inc

Venus Concept (VERO) is trending following news of a significant institutional stake, with one investor now holding 91% of the shares. This has created an extremely tight float, igniting intense community discussion around an unprecedented short squeeze potential and a "float lock" that many believe will drive substantial price volatility as available shares become scarce.

Ondas Holdings, Inc. engages in the development, marketing, and sale of wireless radio systems for secure, wide area mission-critical business-to-business networks. It operates through the Ondas Networks and Ondas Autonomous Systems segments. The Ondas Networks segment provides wireless connectivity solutions enabling mission-critical Industrial Internet applications and services. The Ondas Autonomous Systems segment designs, develops, and markets commercial drone solutions via the Optimus System and Scout System. The company was founded on December 22, 2014 and is headquartered in West Palm Beach, FL.

Ondas Holdings Inc

Ondas Holdings is trending after its Investor Day, where the company announced significantly raised revenue guidance for a future fiscal year, reported strong preliminary results, and highlighted a substantial increase in its cash balance and backlog. The community is actively discussing these updates, with many bulls emphasizing the company's robust fundamentals and anticipated growth in the defense and drone sectors. However, others express caution, citing a rich valuation and perceived market dynamics that may be currently influencing the stock's movement.

ImmunityBio, Inc. is a clinical stage immunotherapy company. It develops next generation therapies that drive immunogenic mechanisms for defeating cancers and infectious diseases. The company's immunotherapy platform activates both the innate and adaptive immune systems to create long term immunological memory. ImmunityBio was founded by Patrick Soon-Shiong in 2014 and is headquartered in San Diego, CA.

ImmunityBio Inc

ImmunityBio (IBRX) is experiencing significant market attention driven by recent compelling clinical trial data for its ANKTIVA treatment, demonstrating impressive complete response rates and durability in bladder cancer, coupled with a notable Saudi Arabian approval for lung cancer. The community is actively discussing a potential massive short squeeze, fueled by exceptionally high trading volume and a strong belief in the company's transformative potential in global cancer treatment. Investors are eyeing its long-term pipeline and the possibility of broader regulatory approvals expanding its market significantly.

SU Group Holdings Ltd. engages in the provision of security-related engineering services, and security guarding and screening services. It operates through the Security-Related Engineering Services and Security Guarding and Screening Services segments. The company was founded by Ming Chan in 1998 and is headquartered in Hong Kong.

SU Group Holdings Ltd. - Ordinary Shares - Class A

SU Group Holdings Ltd

SU Group Holdings Ltd ($SUGP) is trending due to widespread community discussion focused on its ultra-low share float and significant short interest, sparking intense speculation about a potential short squeeze. Traders are actively drawing comparisons to past high-volatility stocks, with sentiment further fueled by a high cost to borrow and anticipation of upcoming earnings or contract news as potential catalysts for a substantial price movement.

IREN Ltd. is a vertically integrated data center business powering the future of Bitcoin, AI and beyond with renewable energy. It is strategically located in renewable-rich, fiber-connected regions across the US and Canada. IREN’s large-scale, grid-connected facilities are purpose-built for the next generation of power-dense computing applications. The company was founded by Daniel Roberts and William Roberts on November 6, 2018, and is headquartered in Sydney, Australia.

IREN Ltd.

IREN Limited

IREN is trending following a significant upgrade by H.C. Wainwright & Co. to a Buy rating with an $80 price target, fueling broad bullish sentiment and discussions of a potential short squeeze. The community is actively speculating about imminent major AI cloud deals with new partners like Anthropic or xAI, further emphasizing IREN's strategic advantage with its existing power capacity and Microsoft contract in the booming AI infrastructure sector.

DraftKings, Inc. is a digital sports entertainment and gaming company, which engages in the provision of online sports betting, online casino, daily fantasy sports product offerings, DraftKings Marketplace, retail sportsbook, media, and other consumer product offerings. The company was founded by Jason D. Robins, Matthew Kalish, and Paul Liberman on December 31, 2011 and is headquartered in Boston, MA.

DraftKings Inc. - Ordinary Shares - Class A

DraftKings Inc

DraftKings is trending as community discussion heats up over recent college sports betting scandals and the evolving landscape of prediction markets, creating market volatility. This comes despite notable analyst upgrades and significant institutional buying, leading to a split in investor sentiment. Many are capitalizing on dips ahead of major sporting events and anticipated strong earnings, while frustrated investors lament perceived market manipulation and the stock's recent performance.

Novo Nordisk A/S is a global healthcare company, which engages in the discovery, development, manufacturing and marketing of pharmaceutical products. It operates through the Diabetes and Obesity Care, and Rare Disease segments. The Diabetes and Obesity Care segment includes diabetes, obesity, cardiovascular, and emerging therapy areas. The Rare Disease segment refers to rare blood disorders, rare endocrine disorders, and hormone replacement therapy. The company was founded by Harald Pedersen and Thorvald Pedersen in 1923 is headquartered in Bagsværd, Denmark.

Novo Nordisk - ADR

Novo Nordisk A/S

Novo Nordisk is surging due to robust early demand for its new oral Wegovy pill and the UK's approval of a higher injectable dose, reinforcing its competitive edge. With a key rival's oral GLP-1 pill facing an FDA delay, the community is enthusiastically discussing NVO's strengthened market position and potential for substantial growth in the obesity treatment sector.

Robinhood Markets, Inc is a financial services platform, which engages in the provision of retail brokerage and offers trading in U.S. listed stocks and Exchange Traded Funds, related options, and cryptocurrency trading, as well as cash management, which includes debit cards services. The company was founded by Vladimir Tenev and Baiju Prafulkumar Bhatt in 2013 and is headquartered in Menlo Park, CA.

Robinhood Markets Inc - Ordinary Shares - Class A

Robinhood Markets Inc

Robinhood is trending due to investor sentiment being impacted by delays surrounding the Digital Asset Market Clarity Act, affecting crypto-adjacent stocks. While some in the community view this as an overreaction and a buying opportunity, others are questioning Robinhood's ability to diversify its business model with initiatives like banking and prediction markets amidst regulatory headwinds.

Riot Platforms, Inc. is a bitcoin mining company, which engages in the provision of special cryptocurrency mining computers. It invests in Verady, Coinsquare, and Tess. It operates through the Bitcoin Mining and Engineering segments. The Bitcoin Mining segment focuses on maximizing ability to successfully mine Bitcoin by growing hash rate. The Engineering segment designs and manufactures power distribution equipment and custom engineered electrical products that provides them the ability to vertically integrate many of the critical electrical components and engineering service. The company was founded on July 24, 2000 and is headquartered in Castle Rock, CO.

Riot Platforms Inc

Riot Platforms is trending following a significant 10-year data center leasing agreement with AMD, signaling a strategic pivot towards AI and high-performance computing infrastructure. The community is actively discussing this development as a key step in re-rating the company as an infrastructure powerhouse with substantial power capacity, diversifying beyond its traditional Bitcoin mining operations.

Cipher Mining, Inc. operates as a Bitcoin mining ecosystem in the United States. The firm is developing a cryptocurrency business. The company was founded in 2021 and is headquartered in New York, NY.

Cipher Mining Inc

Cipher Mining is actively trending after its CEO highlighted robust demand for its AI/HPC data centers and confirmed ongoing discussions for new hyperscaler deals at a recent conference. The community views CIFR as a significant long-term play, often citing its power-first colocation model and existing contracts with major tech firms as reasons for substantial future upside. Despite widespread sentiment about market manipulation suppressing its price, investors remain confident in its strategic pivot beyond traditional Bitcoin mining within the expanding AI infrastructure sector.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

ImmunityBio (NASDAQ:IBRX) Reaches New 1-Year High - Should You Buy?

ImmunityBio (NASDAQ:IBRX) Reaches New 1-Year High - Here's Why...

Morning Market Brief: Clinical Catalysts, First Revenues, and Strategic Deals Drive Early Focus

From oncology to advanced materials and digital health, today’s narrative is about execution.

Functional Force: Precision Platforms Disrupt the 2026 Tumor Landscape

Functional Force: Precision Platforms Disrupt the 2026 Tumor Landscape Functional Force: Precision Platforms Disrupt the 2026 Tumor Landscape PR Newswire VANCOUVER, BC, Jan. 16, 2026 Issued on behalf...

Stocks making the biggest moves premarket: PNC, ImmunityBio, Coupang & more

These are the stocks posting the largest moves in premarket trading...

<ul class="summary-bullets"><li>The trial compares Bacillus Calmette-Guérin (BCG) therapy alone with BCG combined with ANKTIVA.</li><li>Preliminary analysis showed that ANKTIVA plus BCG significantly extended the duration of complete response in BCG-naïve cancer patients.</li><li>ImmunityBio plans to submit a biologics license application to the FDA by the end of 2026.</li></ul>ImmunityBio, Inc. (IBRX) shares jumped 24% in premarket trading on Friday after the company reported a faster than expected enrollment for its QUILT-2.005 bladder cancer drug trial.The company said that enrollment has surpassed internal expectations and is now more than 85% complete, with full enrollment of the planned study population expected by the second quarter of 2026.&nbsp;Based on current progress, ImmunityBio plans to submit a biologics license application to the U.S. Food and Drug Administration (FDA) by the end of 2026.“We look forward to the final accrual of this important registrational randomized trial in patients with BCG-naïve non-muscle-invasive bladder cancer, which represents a substantial proportion of newly diagnosed bladder cancer cases. The interim analysis is encouraging and consistent with findings in the approved BCG-unresponsive setting, where the duration of complete response has exceeded 47 months,” said Patrick Soon-Shiong, M.D., Founder, Executive Chairman, and Global Chief Medical and Scientific Officer of ImmunityBio.Based on current progress, ImmunityBio plans to submit a biologics license application to the FDA by the end of 2026.<h2 class="st-heading-2">What Is The Trial About?</h2>The QUILT-2.005 is a clinical trial for Bacillus Calmette-Guérin (BCG) naïve non-muscle-invasive bladder cancer (NMIBC) that compares standard BCG therapy alone versus BCG combined with ANKTIVA, an Interleukin-15 (IL-15) receptor agonist. IL-15 is an immune system protein that helps develop and activate key cells that work to destroy cancer cells.In 2023, the FDA requested an interim analysis of the randomized trial to evaluate the added benefit of ANKTIVA when combined with BCG, focusing on complete response rates and the durability of response versus BCG alone.The analysis showed that ANKTIVA plus BCG significantly extended the duration of complete response in BCG-naïve NMIBC patients. At six months, 85% of patients receiving the combination maintained a complete response, compared with 57% in the BCG-only group. At nine months, response rates were 84% with combination therapy versus 52% with BCG alone.<h2 class="st-heading-2">How Did Retail React?</h2>Retail sentiment for <a href="https://stocktwits.com/symbol/IBRX">IBRX</a> on Stocktwits remained in the ‘extremely bullish’ zone over the past 24 hours, amid ‘extremely high’ message volumes.<img src="https://news.stocktwits-cdn.com/IBRX_jpg_3d2f27a76b.webp" alt="IBRX.jpg">One user was bullish about the company’s potential.<stembedurl>https://stocktwits.com/Amit18/message/642024906</stembedurl>Another user saw the stock as a long-term runner.<stembedurl>https://stocktwits.com/LeftyT/message/642025351</stembedurl>Over the past year, the stock has gained more than 60%.Read also: <a href="https://stocktwits.com/news-articles/markets/equity/rklb-stock-set-for-all-time-high-morgan-stanley-boost/cmUlAaBR4B7">RKLB Stock Is On Track For Record Open – Here’s What’s Driving The Rally</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

In this photo illustration, an ImmunityBio company logo is seen displayed on a smartphone screen. (Photo Illustration by Piotr Swat/SOPA Images/LightRocket via Getty Images)

Why IBRX Stock Is One Of The Biggest Pre-Market Movers Today 

The company said that enrollment for its randomized registrational QUILT-2.005 trial has surpassed internal expectations and is now more than 85% complete.

 IBRX Stock Rallies As Its Bladder Cancer Study Nears Full Enrollment 

Equity

ImmunityBio Advances First-Line BCG Naive NMIBC Program with Enrollment Exceeding Expectations and Positive Interim Analysis for ANKTIVA Plus BCG

ImmunityBio, Inc. (NASDAQ: IBRX) today announced an update on the status of enrollment in its randomized registrational trial in BCG-nave non-muscle-invasive bladder cancer (NMIBC), QUILT-2.005...

ImmunityBio Announces Durable Complete Response of 15 Months with a Chemotherapy-Free CD19 CAR-NK Cell Therapy in Waldenstrom Lymphoma

ImmunityBio, Inc. (NASDAQ: IBRX), a commercial-stage immunotherapy company, today announced updated efficacy and safety results from the ongoing QUILT-106 clinical study (NCT06334991) evaluating an...

Stock Market Today, Jan. 15: ImmunityBio Surges After Anktiva Revenue Jumps 700%

ImmunityBio (NASDAQ:IBRX), a cancer and infectious-disease drug developer, closed Thursday at $3.95, up 30.79% for the session. The stock jumped after preliminary 2025 results highlighted roughly...

Notable Thursday Option Activity: IBRX, VRT, NN

Looking at options trading activity among components of the Russell 3000 index, there is noteworthy activity today in ImmunityBio Inc (Symbol: IBRX), where a total volume of 77,618 contracts has been...

<ul class="summary-bullets"><li>Analysts on average were expecting the company to report revenue of only $35.99 million for Q4, according to data from Fiscal AI.</li><li>The company’s revenue growth in the quarter was spurred by the accelerating adoption for Anktiva, CEO Richard Adcock said.</li><li>The company said that the Anktiva’s sales momentum “continues to trend upward.”</li></ul>Shares of ImmunityBio, Inc. (IBRX) jumped 28% on Thursday after the company said that it expects net product revenue of approximately $38.3 million for the fourth quarter of 2025, more than five times the revenue it reported in the corresponding quarter of 2024.Analysts on average were expecting the company to report revenue of $35.99 million for the period, according to data from Fiscal.ai.ImmunityBio’s revenue growth in the quarter was spurred by the accelerating adoption for Anktiva, CEO Richard Adcock <a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://www.businesswire.com/news/home/20260115898106/en/ImmunityBio-Reports-Continued-Execution-and-Sales-Momentum-With-%24113-Million-of-Preliminary-Net-Product-Revenuea-700-increase-year-over-year">said</a>. Anktiva is an FDA-approved immunotherapy for non-muscle invasive bladder cancer.<h2 class="st-heading-2">Anktiva Momentum Builds</h2>The company said that the Anktiva’s sales momentum “continues to trend upward.” For full year 2025, the company expects net product revenue of approximately $113.0 million, marking 700% increase year-over-year.Earlier this week, it was reported that the Saudi Food and Drug Authority approved ANKTIVA in combination with the BCG (Bacillus Calmette-Guérin) vaccine to treat adults with BCG-unresponsive non-muscle invasive bladder cancer carcinoma in situ. The agency also approved Anktiva in combination with an immune checkpoint inhibitor for the treatment of metastatic non-small cell lung cancer, marking the company’s first global approval for the indication.ImmunityBio added on Thursday that it ended the quarter with an estimated $242.8 million in cash, cash equivalents, and marketable securities as of December 31, 2025.<h2 class="st-heading-2">How Did Stocktwits Users React?</h2>On Stocktwits, retail sentiment around IBRX stayed within the ‘extremely bullish’ territory over the past 24 hours, while message volume remained at ‘extremely high’ levels.A Stocktwits user said that they now see the stock price breaching the $4 threshold over strong revenue growth and cash on hand. They added that the approvals by the Saudi FDA is a “real catalyst.”<stembedurl>https://www.stocktwits.com/Sisib/message/641960731</stembedurl><a href="https://stocktwits.com/symbol/IBRX">IBRX stock</a> has gained 62% over the past 12 months.&nbsp;Read More: <a href="https://stocktwits.com/news-articles/markets/equity/disc-medicine-sanofi-eli-lilly-shares-slip-on-reports-of-fda-increasing-review-time-for-drugs/cmU1rSfR4JO">Disc Medicine, Sanofi, Eli Lilly Shares Slip On Reports Of FDA Increasing Review Time For Drugs Granted Priority Review Vouchers</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

IBRX Stock Continues Rally — What’s Driving The Optimism Today?

ImmunityBio said that it expects net product revenue of approximately $38.3 million for the fourth quarter of 2025.

Traders are celebrating recent developments for novel treatments like Anktiva, touting potential bladder and lung cancer cures.

Massive trading volume exceeding 100M shares and high short interest are driving speculation for a significant short squeeze.

Optimism stems from accelerated Saudi FDA approval for Anktiva, fueling anticipation of Middle Eastern market expansion and potential investment.

IBRX
ImmunityBio Inc

Feed

News

Sentiment

Earnings

Fundamentals

Info

Latest IBRX News

IBRXImmunityBio Inc